X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

    Oramed Forms a Joint Venture, Oravax Medical for the Development of Novel Oral COVID-19 Vaccines

    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

    Oramed Forms a Joint Venture, Oravax Medical for the Development of Novel Oral COVID-19 Vaccines

    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Oramed Forms a Joint Venture, Oravax Medical for the Development of Novel Oral COVID-19 Vaccines

Content Team by Content Team
22nd March 2021
in Drug Development, Press Statements
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines. The new company, Oravax Medical Inc., is based on Oramed’s proprietary PODâ„¢ oral delivery technology and Premas Biotech Pvt. Ltd.’s novel vaccine technology.

Oravax’s COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine should allow for widescale inoculation and easier distribution of the vaccine without requiring an injection.

In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).

Oravax anticipates commencing a clinical study during the second quarter of 2021.

“An oral COVID-19 vaccine would eliminate several barriers to rapid, widescale distribution, potentially enabling people to take the vaccine themselves at home. While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot,” said Nadav Kidron, CEO of Oramed.

About Oravax Medical Inc.

Oravax was established in 2021 by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech and certain other shareholders with a mission to bring an oral COVID-19 vaccine to the market. Oravax combines cutting edge vaccine technology acquired from Premas Biotech and the proprietary PODâ„¢ oral delivery technology of Oramed Pharmaceuticals.

About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (PODâ„¢) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

Previous Post

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

Related Posts

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Press Statements

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

3rd March 2021
Full service: the expertise and efficiency of a one-stop shop
Drug Development

Full service: the expertise and efficiency of a one-stop shop

26th February 2021
UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca
Packaging & Logistic

UNICEF signs COVID-19 vaccine supply agreement with AstraZeneca

25th February 2021
UCB and Microsoft expand drug development partnership
Drug Development

UCB and Microsoft expand drug development partnership

25th February 2021

Latest News

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
Drug Development

Oramed Forms a Joint Venture, Oravax Medical for the Development of Novel Oral COVID-19 Vaccines

22nd March 2021
Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In